Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

The Use of GnRH Agonists in Feminizing Hormone Therapy Does Not Lead to Negative Metabolic or Bone Health Outcomes in Adult Transgender Women

  • By

  • Brunet, Louise

  • Busiah, Kanetee

  • Moser, Mireille

  • Papadakis, Georgios E.

  • May 21, 2026

Share

  • 1

    GnRH agonists and estrogens in GAHT do not negatively impact metabolic health in adult transgender women.

  • 2

    Body mass index, fat mass index, and visceral adipose tissue remained unchanged during GAHT.

  • 3

    GAHT resulted in a significant reduction in lean mass indices after 12 months of treatment.

  • 4

    Participants showed an increase in plasma HDL-cholesterol levels during GAHT.

  • 5

    The percentage of participants with low bone mineral density decreased from 41% to 27% after 12 months of GAHT.

Original Source(s)

Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women

  • by Brunet, Louise , Busiah, Kanetee , Moser, Mireille , Papadakis, Georgios E.

  • May 21, 2026

Related Content

Metabolically obese normal weight phenotype in children and adolescents aged 3 to 18 years: a systematic review

Beyond identity categories: chronotype and mental health as correlates of sleep quality in transgender and gender-diverse adults

Modified-release hydrocortisone (Efmody®) in children with congenital adrenal hyperplasia: a retrospective registry study